Premium
D2/D3 receptor agonist ropinirole protects dopaminergic cell line against rotenone‐induced apoptosis through inhibition of caspase‐ and JNK‐dependent pathways
Author(s) -
Chen Sheng,
Zhang Xiaojie,
Yang Dehua,
Du Yunlan,
Li Liang,
Li Xuping,
Ming Ming,
Le Weidong
Publication year - 2008
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2008.01.028
Subject(s) - ropinirole , rotenone , neuroprotection , agonist , dopaminergic , protein kinase b , pharmacology , chemistry , apoptosis , p38 mitogen activated protein kinases , receptor , phosphorylation , biology , mapk/erk pathway , endocrinology , dopamine agonist , dopamine , biochemistry , mitochondrion
Ropinirole, a D2/D3 receptor agonist has been reported to have neuroprotective effects. We showed that ropinirole can prevent rotenone‐induced apoptosis in dopaminergic cell line SH‐SY5Y through D3 receptor. We found that ropinirole can block the rotenone‐induced phosphorylation of JNK, P38 and p‐c‐Jun, but promote the phosphorylation of ERK1/2. Furthermore, we demonstrated that ropinirole can reduce the rotenone‐induced cleavages of caspase 9, caspase 3 and PARP and elevate the expression of anti‐apoptotic proteins of p‐Akt and bcl‐2. These results provide a basis for neuroprotection by this drug for the treatment of Parkinson disease.